Advertisement

Organ and Metabolic Complications: Cardiac

  • Patrick S. Parfrey
  • R. N. Foley
  • J. D. Harnett

Abstract

The burden of illness due to cardiac disease in chronic uremia is high. Cardiac disease is the major cause of death in dialysis patients, accounting for about 40% of deaths in dialysis patients (1). When compared to a nonrenal cohort aged 45–64 years the death rate in a dialysis cohort of similar age was 3.5 times higher (2). Indices of morbidity are also high. The prevalence of clinical manifestations of cardiac disease on initiation of ESRD therapy is high (3) (Table 1). The probability of having a myocardial infarction or angina requiring hospitalization in hemodialysis patents is 10%/year (4). There is a similar probability of developing pulmonary edema requiring hospitalization or additional ultrafiltration (4). The prevalence of persistent or recurrent congestive heart failure in patients established on dialysis is 10% (5), Ischemic heart disease 17–34% (6), and complex premature ventricular complexes 18% (7).

Keywords

Ischemic Heart Disease Left Ventricular Hypertrophy Diastolic Dysfunction Dialysis Patient Recombinant Human Erythropoietin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    US Renal Data System, USRDS 1991 Annual Report, Bethesda, Maryland: The National Institute of Diabetes and Digestive and Kidney Diseases, 1991Google Scholar
  2. 2.
    Greaves SC, Sharpe DN: Cardiovascular disease in patients with end stage renal failure. Aust NZ J Med 22: 153, 1992Google Scholar
  3. 3.
    Foley RN, Parfrey PS, Harnett JD, Kent G, Martin CJ, Murray D, Barre PE: Clinical and echocardiographic cardiovascular disease in patients starting end-stage renal disease therapy: prevalence, associations and prognosis. Kidney Int 47: 186, 1995PubMedCrossRefGoogle Scholar
  4. 4.
    Churchill DN, Taylor DW, Cook RJ et al.: Canadian hemodialysis morbidity study. Am J Kidney Dis 19: 214, 1991Google Scholar
  5. 5.
    Parfrey PS, Harnett JD, Griffiths SM, Gault MH, Barre PE: Congestive heart failure in dialysis patients. Arch Int Med 148: 1519, 1988CrossRefGoogle Scholar
  6. 6.
    Rostand SG, Rutsky EA: Ischemic heart disease in chronic renal failure: demography, epidemiology and pathogenesis. in Cardiac Dysfunction in Chronic Uremia, edited by Parfrey PS, Harnett JD, Kluwer Academic Publishers, Boston, 1992, p 53Google Scholar
  7. 7.
    Wizemann V, Kramer W: Cardiac arrhythmias in end stage renal disease: prevalence, risk factors and management, in Cardiac Dysfunction in Chronic Uremia, edited by Parfrey PS, Harnett JD, Kluwer Academic Publishers, Boston, 1992, p 67Google Scholar
  8. 8.
    Rostand SG, Kirk KA, Rutsky EA: Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney Int 25: 653, 1984PubMedCrossRefGoogle Scholar
  9. 9.
    Rostand SG, Kirk KA, Rutsky EA: Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int 22: 304, 1982PubMedCrossRefGoogle Scholar
  10. 10.
    The Multicenter Postinfarction Research Group: Risk stratification and survival after myocardial infarction. N Engl J Med 309: 331, 1983CrossRefGoogle Scholar
  11. 11.
    White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76: 44, 1987PubMedGoogle Scholar
  12. 12.
    Keough AM, Baron DW, Hickie JB: Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol 65: 903, 1990CrossRefGoogle Scholar
  13. 13.
    Lauer MJ, Evans JC, Levy D: Prognostic implications of subclinical left ventricular dilatation in men free of overt cardiovascular disease (The Framingham Heart Study). Am J Cardiol 70: 1180, 1992PubMedCrossRefGoogle Scholar
  14. 14.
    Levy D, Garrison RJ, Savage DD, Kannel WR, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engt J Med 322: 1561, 1990CrossRefGoogle Scholar
  15. 15.
    Casale PN, Devereaux RB, Milner M et al., Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 105: 173, 1986PubMedGoogle Scholar
  16. 16.
    Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114: 345, 1991PubMedGoogle Scholar
  17. 17.
    Silberberg JS, Barre P, Prichard S, Sniderman AD: Left ventricular hypertrophy: an independent determinant of survival in end stage renal failure. Kidney Int 36: 286, 1989PubMedCrossRefGoogle Scholar
  18. 18.
    Hutchins GM: Cardiac pathology in chronic renal failure, in Cardiac Dysfunction in Chronic Uremia, edited by Parfrey PS, Harnett JD, Kluwer Academic Publishers, Boston, 1992, p 85Google Scholar
  19. 19.
    Foley RN, Parfrey PS, Harnett JD: Left ventricular hypertrophy in dialysis patients. Seminars in Dialysis 5: 34, 1992CrossRefGoogle Scholar
  20. 20.
    Heng MK, Janz RF, Jobin J: Estimation of regional stress in the left ventricular septum and free wall: an echocardiographic study suggesting a mechanism for asymmetric septal hypertrophy. Am Heart J 110: 84, 1985PubMedCrossRefGoogle Scholar
  21. 21.
    Bernardi D, Bemini L, Cini G, Ghione S, Bonechi I; Asymmetric septal hypertrophy and sympathetic overactivity in normotensive hemodialyzed patients. Am Heart J 109: 539, 1985PubMedCrossRefGoogle Scholar
  22. 22.
    London GM, Fabiani F, Marchais SJ, de Vernejoul M-C, Guerin AP, Safar ME, Metivier F, Llach F: Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int 31: 911, 1987CrossRefGoogle Scholar
  23. 23.
    Wever KT: Cardiac interstitium in health and disease: the fibrillar Collagen Network. J Am Coll Cardiol 13: 1637, 1989CrossRefGoogle Scholar
  24. 24.
    Mall G, Huter W, Schneider J, Lundin P, Ritz E: Diffuse intermyocardiocytic fibrosis in uremic patients. Nephrol Dial Transplant 5: 39, 1990PubMedGoogle Scholar
  25. 25.
    Hess OM, Schneider J, Koch R, Bamert C, Grimm J, Krayenbuehl HP: Diastolic function and myocardial structure in patients with myocardial hypertrophy. Circulation 63:360, 1981PubMedGoogle Scholar
  26. 26.
    McLenachan JM, Henderson E, Dargie HJ: A possible mechanism of sudden death in hypertensive left ventricular hypertrophy. J Hypertension 5(Suppl 5): 630, 1987Google Scholar
  27. 27.
    Rostand SG, Rutsky EA: Ischemic heart disease in chronic renal failure: management considerations. Semin Dial 2: 98, 1989CrossRefGoogle Scholar
  28. 28.
    Palmer BF, Henrich WL: The effect of dialysis on left ventricular contractibility, in Cardiac Dysfunction in Chronic Uremia, edited by Parfrey PS, Harnett, JD, Kluwer Academic Publishers, Boston, 1992, p 171Google Scholar
  29. 29.
    Daugirdas JT: Dialysis hypotension: a hemodynamic analysis. Kidney Int 39: 233, 1991PubMedCrossRefGoogle Scholar
  30. 30.
    Madsen BR, Alpert MA, Shiting RB, Van Stone J, Ahmad M, Kelly DL: Effect of hemodialysis on left ventricular performance. Analysis of echocardiographic subsets. Am J Nephrol 4: 86, 1984PubMedGoogle Scholar
  31. 31.
    Hung J, Harris PJ, Uren RF, Tiller DJ, Kelly DT: Uremic cardiomyopathy — effect of hemodialysis on left ventricular function in end-stage renal failure. N Engl J Med 302(10): 547, 1980PubMedCrossRefGoogle Scholar
  32. 32.
    Ruffmann K, Mandelbaum A, Bowmer J et al.: Doppler echocardiographic findings in dialysis patients. Nephrol Dial Transplant 5: 426, 1990PubMedGoogle Scholar
  33. 33.
    Harnett JD, Murphy B, Collingwood P, Purchase L, Kent G, Parfrey PS: The reliability and validity of echocardiographic measurement of left ventricular mass index in hemodialysis patients. Nephron 65: 212, 1993PubMedGoogle Scholar
  34. 34.
    Hutchinson TA, Thomas CD, MacGibbon B: Predicting survival in adults with end stage renal failure; an age-equivalence index. Ann Intern Med 96: 417, 1982PubMedGoogle Scholar
  35. 35.
    Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: Left ventricular geometry: a critical prognostic variable in ESRD patients. J Am Soc Nephrol 5: 2024, 1995PubMedGoogle Scholar
  36. 36.
    Foley RN, Parfrey PS, Harnett JD, Kent G, Barre PE: Uremia related prognostic factors in dialysis patients: a cohort study from the start of dialysis therapy. JASN 4: 346, 1993Google Scholar
  37. 37.
    Harnett JD, Parfrey PS, Foley RN, Kent GM, Barre PE: Anemia: an important risk factor for cardiovascular morbidity and mortality in dialysis patients. JASN 4: 346, 1993Google Scholar
  38. 38.
    Iseki K, Kawazoe N, Fukiyama K: Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int 44: 115, 1993PubMedCrossRefGoogle Scholar
  39. 39.
    Owen OF, Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction rato and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329: 1001, 1993PubMedCrossRefGoogle Scholar
  40. 40.
    Levy D, Wilson PWF, Anderson KM et al.: Stratifying the patient at risk from coronary disease: new insights from the Framingham Heart Study. Am Heart J 119: 712, 1990PubMedCrossRefGoogle Scholar
  41. 41.
    Gordon T, Kannel WB: Multiple risk factors for predicting coronary heart disease: the concept, accuracy and application. Am Heart J 103: 1031, 1982PubMedCrossRefGoogle Scholar
  42. 42.
    Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann Intern Med 110: 105, 1989Google Scholar
  43. 43.
    Shapiro RJ: Atherogenesis in chronic renal failure, in Cardiac Dysfunction in Chronic Uremia, edited by Parfrey PS, Harnett JD, Kluwer Academic Publishers, Boston, 1992, p 187Google Scholar
  44. 44.
    Lal SM: Hyperlipidemia in continuous ambulatory peritoneal dialysis patients. ASAIO J 39: 87, 1993PubMedCrossRefGoogle Scholar
  45. 45.
    Aronow WS, Epstein S, Koengsberg M: Usefulness of echocardiographic left ventricular hypertrophy and silent ischemia in predicting new cardiac events in elderly patients with systemic hypertension and coronary artery disease. Angiology 41: 189, 1990PubMedCrossRefGoogle Scholar
  46. 46.
    Harnett JD, Foley RN, Kent GM, Murray DC, Barre PE, Parfrey PS: Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47: 884, 1995PubMedCrossRefGoogle Scholar
  47. 47.
    Burt RK, Gupta-Burt S, Suki WN et al.: Reversal of left ventricular dysfunction after renal transplantation. Ann Intern Med 111: 635, 1989PubMedGoogle Scholar
  48. 48.
    London GM, De Vernejoul MC, Fabiani F et al: Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney Int 32: 900, 1987PubMedCrossRefGoogle Scholar
  49. 49.
    London GM, Fabiani F: Left ventricular dysfunction in end-stage renal disease: echocardiographic insights, in Cardiac Dysfunction in Chronic Uremia, edited by Parfrey PS, Harnett JD, Kluwer Academic Publishers, Boston, 1992, p 125Google Scholar
  50. 50.
    Harnett JD, Parfrey PS, Griffiths SM, Gault MH, Barre P, Guttman RD: Left ventricular hypertrophy in end stage renal disease. Nephron 48: 107, 1988PubMedGoogle Scholar
  51. 51.
    Harnett JD, Kent GM, Barre PE, Taylor R. Parfrey PS: The development of left ventricular hypertrophy in dialysis patients: a nested case control study. J Am Soc Nephrol 4: 1486, 1994PubMedGoogle Scholar
  52. 52.
    Cannella G, Paoletti E, Delfino R et al.: Regression of left ventricular hypertrophy in hypertensive dialysed uremic patients on long-term antihypertensive therapy. Kidney Int 44: 881, 1993PubMedCrossRefGoogle Scholar
  53. 53.
    Parfrey PS, Harnett JD, Foley RN, Kent GM, Murray DC, Barre PE, Guttmann RD: Impact of renal transplatation on uremic cardiomyopathy. Transplatation 1995. (In press)Google Scholar
  54. 54.
    London GM, Zins B, Pannier B et al.: Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 36: 878, 1989PubMedCrossRefGoogle Scholar
  55. 55.
    MacDougall IC, Lewis NP, Saunders MJ et al.: Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 335: 489, 1993CrossRefGoogle Scholar
  56. 56.
    Silberberg J, Racine N, Barre P, Sniderman AD: Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Card 6: 1, 1990Google Scholar
  57. 57.
    Cannella G, LaCanna G, Sandrini M et al.: Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anemia dialysed uremic patients. Nephrol Dial Transplant 6: 31, 1993Google Scholar
  58. 58.
    Low-Friedrich I, Grutzmacher P, Marz W, Bergman M, Schoeppe W: Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol 11: 54, 1991PubMedCrossRefGoogle Scholar
  59. 59.
    Pascual J, Teruel JL, Moya JL, Liano F, Jimenez-Mena M, Ortuno J: Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 35: 280, 1991PubMedGoogle Scholar
  60. 60.
    Goldberg N, Lundin AP, Delano B, Friedman EA, Stien RA: Changes in left ventricle size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J 124(2): 424, 1992PubMedCrossRefGoogle Scholar
  61. 61.
    Martinez-Vea A, Bardaji A, Garcia C, Ridao C, Richart C, Oliver JA: Long term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis. Am J Kidney XIX(4): 353, 1992Google Scholar
  62. 62.
    Zehnder C, Zuber M, Sulzer M, Meyer B, Straumann F, Jenzer HR, Blumberg A: Influence of longterm amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 61:21, 1992PubMedGoogle Scholar
  63. 63.
    Harnett JD, Le H, Parfrey PS: The importance of blood pressure control in dialysis patients receiving erythropoietin. JASN 3(3): 426, 1992 AbstractGoogle Scholar
  64. 64.
    Bromlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and biochemical basis of diabetic complications. N Engl J Med 318: 1315, 1988CrossRefGoogle Scholar
  65. 65.
    Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham Study. JAMA 241: 2035, 1979PubMedCrossRefGoogle Scholar
  66. 66.
    Valsania P, Zarich SW, Kowalchuk GJ, Kosinski E, Warram JH, Krolewski AS: Severity of coronary artery disease in young patients with insulin-dependent diabetes mellitus. Am Heart J 122:695, 1991PubMedCrossRefGoogle Scholar
  67. 67.
    Galderisi M, Anderson KM, Wilson PWF, Levy D: Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study). Am J Cardiol 68: 85, 1991PubMedCrossRefGoogle Scholar
  68. 68.
    Grossman E, Shemesh J, Shamiss A, Thaler M, Carroll J, Rosenthal T: Left ventricular mass in diabetes-hypertension. Arch Intern Med 152: 1001, 1992PubMedCrossRefGoogle Scholar
  69. 69.
    van Hoeven KH, Factor SM: A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensivediabetic heart disease. Circulation 82: 848, 1990PubMedGoogle Scholar
  70. 70.
    Sytkowski PA, Kannel WB, D’Agostino RB: Changes in risk factors and the decline in cardiovascular mortality. The Framingham Study. N Engl J Med 311: 1144, 1990Google Scholar
  71. 71.
    The SOLVD investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293, 1991CrossRefGoogle Scholar
  72. 72.
    The SOLVD investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685, 1992CrossRefGoogle Scholar
  73. 73.
    Jaeschke R, Oxman AD, Guyatt GH: To what extent do congestive heart failure patients in sinus rhythm benefit from Digoxin therapy? A systematic overview and metaanalysis. Am J Med 88: 279, 1990PubMedCrossRefGoogle Scholar
  74. 74.
    Pacrer M, Cheorghiade M, Young JB et al. for the RADIANCE Study: Withdrawal of digoxin from patients with chronic heart failure treated with antiotension-converting-enzyme inhibitors. N Engl J Med 329: 1, 1993CrossRefGoogle Scholar
  75. 75.
    Wizemann V, Kaufmann J, Kramer W: Effect of ery-thropoietin on ischemia tolerance in anemia hemodialysis patients with confirmed coronary artery disease. Nephron 62: 161, 1992PubMedGoogle Scholar
  76. 76.
    Ritz E, Koch M: Morbidity and mortality due to hypertension in patients with renal failure. Am J Kid Dis 21: 113, 1993PubMedGoogle Scholar
  77. 77.
    Cheigh JS, Milite C, Sullivan JF, Rubin AL, Stenzel KH: Hypertension is not adequately controlled in hemodialysis patients. Am J Kid Dis 14: 453, 1992Google Scholar
  78. 78.
    American College of Physicians: Automated ambulatory blood pressure and self-measured blood pressure monitoring devices: their role in the diagnosis and management of hypertension. Ann Int Med 118: 889, 1993Google Scholar
  79. 79.
    Baumgart P, Walger P, Gerke M, Dorst KG, Vetter H, Rahn KH: Nocturnal hypertension in renal failure, hemodialysis and after renal transplantation. J Hypertens 7: S70, 1989CrossRefGoogle Scholar
  80. 80.
    Van de Bourne P, Tielemans C, Collait F, Vanherweghem J-L, Degaute J-P: Twenty-four hour blood pressure and heart rate patterns in chronic hemodialysis patients. Am J Kid Dis 22: 419, 1993Google Scholar
  81. 81.
    Parfrey PS, Harriett JD, Griffiths SM: The clinical course of left ventricular hypertrophy in dialysis patients. Nephron 55: 114, 1990PubMedGoogle Scholar
  82. 82.
    Daholf B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 5: 95, 1992Google Scholar
  83. 83.
    Lovastatin Pravastatin Study Group: A multicenter comparative trial of lovastatin and prevastatin in the treatment of hypercholesterolemia. Am J Cardioll 71: 810, 1993CrossRefGoogle Scholar
  84. 84.
    Brown G, Albert JJ, Fisher LD et al.: Regression of coronary artery disease as a result of intensive, lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323: 1289, 1990PubMedCrossRefGoogle Scholar
  85. 85.
    Seres DS, Strain GW, Haskim SA, Goldberg IJ. Levin NW: Improvement of lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol 3: 1409. 1993PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Patrick S. Parfrey
    • 1
  • R. N. Foley
    • 1
  • J. D. Harnett
    • 1
  1. 1.Division of Nephrology The Health Sciences CenterMemorial UniversitySt. JohnsCanada

Personalised recommendations